Zenas BioPharma outlines Phase 3 trial design for orelabrutinib in MS
Zenas BioPharma will present updates on orelabrutinib and obexelimab at MSToronto2026, including Phase 3 trial designs for orelabrutinib in non-active secondary progressive multiple sclerosis and primary progressive multiple sclerosis. New results from a Phase 2 relapsing-remitting multiple sclerosis study of orelabrut